CHRISTOPHER NOGGLE: Open Payments
NPI 1154107209 · FLINT, MI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$731 in 30 payments from 9 companies in 2025. Trend: 2023 $439 · 2024 $1,073 · 2025 $731
Food & beverage: $731
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 9 | $183 |
| ABBVIE INC. | 13 | $173 |
| E.R. Squibb & Sons, L.L.C. | 2 | $135 |
| Janssen Pharmaceuticals, Inc | 1 | $86 |
| Otsuka America Pharmaceutical, Inc. | 1 | $74 |
| Vanda Pharmaceuticals Inc. | 1 | $24 |
| Novo Nordisk Inc | 1 | $22 |
| Teva Pharmaceuticals USA, Inc. | 1 | $18 |
| Neurocrine BioSciences, Inc. | 1 | $17 |
Products named: CAPLYTA, VRAYLAR, COBENFY, SPRAVATO, REXULTI, FANAPT, Ozempic, UZEDY.
Industry payments across MI — which companies pay providers there.
